Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
YSBHKSE:09885 +6.77%74 Net Margin % is 1.08% as of Jun. 2026. GuruFocus rates HKSE:09885 with a GF Score™ of 74/100 and a GF Value™ of HK$7.39 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 667 Healthcare Providers & Services companies, YSB ranks worse than 60.57% on this metric.
Net margin is calculated as Net Income divided by its Revenue. YSB's Net Income for the
six
months ended in Jun. 2026 was HK$128 Mil. YSB's Revenue for the
six
months ended in Jun. 2026 was HK$11,895 Mil. Therefore, YSB's net margin for the quarter that ended in Jun. 2026 was 1.08%.
The historical rank and industry rank for YSB's Net Margin % or its related term are showing as below:
HKSE:09885'
s Net Margin % Range Over the Past 10 Years
Min: -18.89 Med: -7.2 Max: 0.87
Current: 0.87
HKSE:09885's Net Margin % is ranked worse than 60.57% of 667
companies
in the Healthcare Providers & Services industry
Industry Median: 2.92
vs HKSE:09885: 0.87
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
YSB Net Margin % Related Terms
YSB Net Margin % Historical Data
* Premium members only.
The historical data trend for YSB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, YSB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YSB Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, YSB's Net Margin % distribution charts can be found below:
* The bar in red indicates where YSB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YSB (HKSE:09885) has a Net Margin % of 1.08% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on YSB and its competitors. According to the industry distribution chart, YSB ranks #404 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 60.6%.
Is YSB's Net Margin % too high?
YSB's current Net Margin % is 1.08%. The Healthcare Providers & Services industry median Net Margin % is 2.92. YSB's value of 1.08% is 63% below this industry median. Based on the distribution chart, YSB ranks #404 out of 667 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, YSB has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does YSB's Net Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, YSB ranks #404 out of 667 companies for Net Margin %. This places YSB in the lower half of its industry. The industry median Net Margin % is 2.92. YSB's value of 1.08% is 63% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.92, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. YSB's current Net Margin % of 1.08% is 63% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on YSB and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. YSB's current Net Margin % is 1.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YSB stock overvalued right now?
Based on GuruFocus' analysis, YSB (HKSE:09885) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$7.39, compared to a current price of HK$3.55 — trading 52% below its estimated fair value. The current Net Margin % is 1.08% and 63% below the Healthcare Providers & Services industry median of 2.92. YSB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For YSB (HKSE:09885), the current Net Margin % is 1.08% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is YSB (HKSE:09885) Overvalued in 2026?
Based on GuruFocus' analysis, YSB stock appears to be undervalued.
The current stock price of HK$3.55 is trading 52% below its estimated GF Value™ of HK$7.39.
GuruFocus considers YSB to be Significantly Undervalued.
Key valuation signals for HKSE:09885:
Net Margin %: 1.08%
GF Value™: HK$7.39 vs. price of HK$3.55 (52% below fair value)
Industry Position: 63% below the Healthcare Providers & Services median (#404 of 667)
No single metric tells the full story. See the HKSE:09885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The group is engaged in the wholesale and retail of pharmaceutical and healthcare products through offline channels, retail shops, and its online platform. It also operates an online marketplace that enables pharmaceutical distributors and vendors to sell pharmaceutical and healthcare products through the Group's platform. In addition, the Group provides SaaS solutions to downstream pharmacies and primary healthcare institutions to streamline inventory and patient management, and offers system technologies and operational support services through smart healthcare systems, integrated point-of-care testing and monitoring devices, digital management systems, and smart AI doctor-aid systems.
74GF Score
Get the complete analysis for HKSE:09885
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09885 has been successfully added to your 
